Skip to main content

Table 2 Estimated incident rates for all-cause mortality, cardiovascular events, and bone disorder-related to ESRD

From: Effectiveness of phosphate binders on mortality and cardiovascular disease in end-stage renal disease patients with hyperphosphatemia: a multicenter real-world cohort study

Treatment approaches

Treatments

All-cause mortality

CVD

Bone disorder

No events (Person-year)

IR/100/ years

No events (Person-year)

IR/100/ years

No events (Person-year)

IR/100/ years

ITT

No-PBs

1,146 (16,193.7)

7.1 (6.7, 7.5)

820 (8,981.6)

9.1 (8.5, 9.8)

117 (15,240.8)

0.8 (0.6, 0.9)

CBPBs

1,994 (19,293.5)

10.3 (9.9, 10.8)

1,211 (9,091.4)

13.3 (12.6, 14.1)

426 (15,949.3)

2.7 (2.4, 2.9)

NCBPBs

41 (443.2)

9.2 (6.8, 12.6)

24 (232.9)

10.30 (6.9, 15.4)

12 (394.9)

3.0 (1.7, 55.4)

Aluminum hydroxide

45 (425.4)

10.6 (7.9, 14.2)

27 (254.7)

10.6 (7.3, 15.5)

14 (367.9)

3.8 (2.3, 6.4)

Overall

3,226 (36,355.1)

8.9 (8.6, 9.2)

2,082 (18,560.6)

11.2 (10.7, 11.7)

569 (31,952.9)

1.8 (1.6, 1.9)

PPA

No-PBs

1,146 (16,193.7)

7.1 (6.7, 7.5)

820 (8,981.6)

9.1 (8.5, 9.8)

117 (15,240.8)

0.8 (0.6, 0.9)

CBPBs

1,619 (13,147.8)

12.3 (11.7, 12.9)

890 (6,518.2)

13.7 (12.7, 14.6)

287 (10,861.7)

2.6 (2.3, 2.9)

NCBPBs

17 (139.3)

12.2 (7.6, 19.6)

10 (96.7)

10.34 (5.6, 19.2)

4 (131.7)

3.0 (1.1, 8.1)

Aluminum hydroxide

4 (12.7)

31.5 (11.8, 83.9)

0 (3.6)

0

0 (12.7)

0

Overall

2,748 (29,493.5)

9.8 (9.5, 10.2)

1,720 (15,600.14)

11.0 (10.5, 11.6)

408 (24,980.9)

1.6 (1.5, 1.8)

Actual treatment-patterns

No-PBs

1,146 (16,193.7)

7.1 (6.7, 7.5)

820 (8,981.6)

9.1 (8.5, 9.8)

117 (15,240.8)

0.8 (0.6, 0.9)

CBPBs-CBPBs

1,749 (14,989.2)

11.7 (11.1, 12.2)

1,111 (7,928.4)

14.0 (13.2, 14.8)

347 (12,502.1)

2.8 (2.5, 3.1)

CBPBs-NCBPBs

165 (2,758.7)

6.0 (5.1, 7.0)

57 (473.6)

12.1 (9.4, 15.7)

46 (2,135.4)

2.2 (1.6, 2.9)

CBPBs-Aluminum

37 (626.1)

5.9 (4.3, 8.2)

16 (112.0)

14.3 (8.6, 23.3)

10 (542.6)

1.8 (1.0, 3.4)

Overall

3,097 (34,567.7)

9.0 (8.6, 9.3)

1,990 (17,495.6)

11.4 (10.9, 11.9)

520 (30,420.9)

1.7 (1.6, 1.9)

  1. Abbreviations: CBPBs; Calcium-based phosphate binders, CVD; Cardiovascular disease, CSMBS; IR; Incidence rate, ITT; Intention to treat, NCBPBs; N; Number, Non-calcium-based phosphate binders i.e., lanthanum or sevelamer; PBs; Phosphate binders, PPA; Per-protocol analysis
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us